List of Opsumit drug patents

Opsumit is owned by Actelion.

Opsumit contains Macitentan.

Opsumit has a total of 5 drug patents out of which 0 drug patents have expired.

Opsumit was authorised for market use on 18 October, 2013.

Opsumit is available in tablet;oral dosage forms.

Opsumit can be used as method of treating pulmonary hypertension comprising administering macitentan in combination with a compound having phosphodiesterase-5 inhibitory properties, method of treating pulmonary arterial hypertension by administering a pharmaceutical composition comprising macitentan and a polysorbate, wherein the polysorbate represents 0.1 to 3% of the weight of said pharmaceutical composition, method of treating pulmonary arterial hypertension by administering a pharmaceutical composition comprising macitentan and a polysorbate, wherin the polysorbate represents 0.1 to 1% of the weight of said pharmaceutical composition.

The generics of Opsumit are possible to be released after 18 April, 2029.

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US7094781 ACTELION Sulfamides and their use as endothelin receptor antagonists
Dec, 2025

(2 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10946015 ACTELION Stable pharmaceutical compositions comprising a pyrimidine-sulfamide
Sep, 2026

(3 years from now)

US9265762 ACTELION Stable pharmaceutical compositions comprising a pyrimidine-sulfamide
May, 2027

(4 years from now)

US8367685 ACTELION Stable pharmaceutical compositions comprising a pyrimidine-sulfamide
Oct, 2028

(5 years from now)

US8268847 ACTELION Therapeutic compositions comprising a specific endothelin receptor antagonist and a PDE5 inhibitor
Apr, 2029

(6 years from now)

Drugs and Companies using MACITENTAN ingredient

Market Authorisation Date: 18 October, 2013

Treatment: Method of treating pulmonary arterial hypertension by administering a pharmaceutical composition comprising macitentan and a polysorbate, wherin the polysorbate represents 0.1 to 1% of the weight of said pharmaceutical composition; Method of treating pulmonary arterial hypertension by administering a pharmaceutical composition comprising macitentan and a polysorbate, wherein the polysorbate represents 0.1 to 3% of the weight of said pharmaceutical composition; Method of treating pulmonary hypertension comprising administering macitentan in combination with a compound having phosphodiesterase-5 inhibitory properties

Dosage: TABLET;ORAL

How can I launch a generic of OPSUMIT before it's patent expiration?
More Information on Dosage

availability in other generic markets.

Click on the highlighted region to filter.

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic

Other things you might be interested in